DK Street Journal

SMID Biotech Takeout Cohort's 73% Year Is a Two-Speed Story

Prompt v1.0

The Barrons SMID biotech takeout bucket's +72.8% one-year return is real but concentrated in CGON, DYN and CYTK, while ALNY and MLTX are outright drags -- including a violent MLTX single-day crash the original thesis said didn't happen. Six of eight names remain in strongly bullish bands and the M&A/financing backdrop is genuinely accelerating, but ALNY, ASND and CYTK have grown too large for the bolt-on-sized deals actually getting done in 2026.

ASNDMLTXDYNPCVXCYTKCGONDNLIALNY
TickerCompanySegmentTrend · 13mo30D1Y
ASNDAscendis Pharma A/SAutoimmune & Inflammatory Diseases🟢 Cont. Bull−4.4%+54.3%
MLTXMoonLake ImmunotherapeuticsMonoclonal Antibodies & Immunotherapies🟢 Cont. Bull−7.7%−64.9%
DYNDyne TherapeuticsOther🟢 Cont. Bull+18.1%+172.8%
PCVXVaxcyteVaccines & Infectious Disease🟢 Cont. Bull−8.2%+52.8%
CYTKCytokinetics, IncorporatedOther🟢 Cont. Bull−10.2%+118.3%
CGONCG OncologyOther🟢 Cont. Bull−6.3%+165.4%
DNLIDenali TherapeuticsOther🟢 Cont. Bull−7.9%+75.2%
ALNYAlnylam PharmaceuticalsGene & RNA Therapeutics🔴 Cont. Bear−2.4%−13.3%

12-month price & trend

ASND
Ascendis Pharma A/S
252
−2.39 (−0.94%)
vs. prior close
Price20d50d150d
ASND 12-month price
Autoimmune & Inflammatory Diseases
MLTX
MoonLake Immunotherapeutics
18.38
−0.33 (−1.76%)
vs. prior close
Price20d50d150d
MLTX 12-month price
Monoclonal Antibodies & Immunotherapies
DYN
Dyne Therapeutics
25.10
−0.80 (−3.09%)
vs. prior close
Price20d50d150d
DYN 12-month price
Other
TickerMkt capP/EP/E fwdP/SP/S fwdP/GPP/GP fwdEV/EBITDAFCF yld
ASND$14.0B16.4x16.2x11.7x10.4x12.9x11.5x152.8x2.7%
MLTX$1.6Bn/m—n/m———n/m-14.5%
DYN$3.0Bn/m—n/m———n/m-16.7%
PCVX
Vaxcyte
52.98
−1.62 (−2.97%)
vs. prior close
Price20d50d150d
PCVX 12-month price
Vaccines & Infectious Disease
CYTK
Cytokinetics, Incorporated
78.39
−1.06 (−1.34%)
vs. prior close
Price20d50d150d
CYTK 12-month price
Other
CGON
CG Oncology
69.12
−3.50 (−4.82%)
vs. prior close
Price20d50d150d
CGON 12-month price
Other
TickerMkt capP/EP/E fwdP/SP/S fwdP/GPP/GP fwdEV/EBITDAFCF yld
PCVX$8.4Bn/m—n/m335.4x——n/m-14.3%
CYTK$8.0Bn/m—113.4x53.7x133.4x63.2xn/m-7.2%
CGON$6.3Bn/m——568.3x——n/m-2.6%
DNLI
Denali Therapeutics
23.85
−0.20 (−0.83%)
vs. prior close
Price20d50d150d
DNLI 12-month price
Other
ALNY
Alnylam Pharmaceuticals
287
−1.79 (−0.62%)
vs. prior close
Price20d50d150d
ALNY 12-month price
Gene & RNA Therapeutics
TickerMkt capP/EP/E fwdP/SP/S fwdP/GPP/GP fwdEV/EBITDAFCF yld
DNLI$3.7Bn/m—n/m104.4x——n/m-11.5%
ALNY$34.2B42.0x38.4x7.1x6.3x8.9x7.9x29.4x1.6%

Consensus projections

TickerFY2026EFY2027EFY2028E
ASNDRevenue+90.9%+46.5%+27.1%
EPS−516.5%−35.2%+58.5%
MLTXRevenue——+499.2%
EPS+6.4%−5.3%−19.5%
DYNRevenue+43.8%+5202.8%+423.5%
EPS+3.5%−7.7%−24.6%
PCVXRevenue—+248.6%+103.3%
EPS+51.9%−19.8%−5.5%
CYTKRevenue+94.8%+182.8%+110.5%
EPS−6.8%−26.1%−52.9%
CGONRevenue+292.5%+669.5%+432.7%
EPS+26.5%+2.4%−97.0%
DNLIRevenue+1299.4%+204.0%+150.9%
EPS−18.1%+0.8%−24.6%
ALNYRevenue+45.6%+26.9%+19.6%
EPS+171.3%+51.0%+24.2%

Forward fiscal years only. Blank means no analyst coverage for that year.

The two-speed year

The headline +72.8% one-year average return for the eight-name bucket (ALNY, ASND, CGON, CYTK, DNLI, DYN, MLTX, PCVX) checks out exactly, but it is not broad-based. CGON (+180.9%), DYN (+178.2%) and CYTK (+116.9%) carry the bucket, while ALNY (-11.2%) and MLTX (-65.7%) are drags. The MLTX number is the biggest correction to the original thesis: the stock did not have a gradual re-rating -- it crashed roughly 90% in a single session on September 29, 2025 after Phase 3 VELA data showed sonelokimab was uncompetitive with Bimzelx in hidradenitis suppurativa, a result that also triggered a securities fraud class action. Alnylam tells a different but equally unflattering story: it rotated from strongly bullish in mid-2025 into strongly bearish for most of Jan-June 2026 and now sits in mildly bearish, the bucket's only bear-band name, after concerning 2026/2030 guidance sent shares down nearly 19% between October 2025 and January 2026.

Why the flat month isn't a rollover

Despite the -1.6% average 30-day return, the intact-trend read holds up: six of eight names (ASND, CGON, CYTK, DNLI, DYN, MLTX) currently sit in strongly bullish bands and PCVX is mildly bullish -- only ALNY is bearish. The flat month is a shallow, broad pullback (seven of eight names down 1.5-9%) almost entirely offset by DYN's +21.8% surge, which itself reflects an abrupt reversal rather than a slow grind: DYN was in a strongly bearish band as recently as June 1 before flipping to strongly bullish by June 23, coinciding with completion of enrollment in Dyne's ACHIEVE registrational trial for DM1, a move Yahoo Finance tied to growing confidence in Dyne's late-stage neuromuscular pipeline. ASND's mildly bullish-to-strongly bullish upgrade on July 2 is confirmed and coincides with an accelerating Yorvipath launch: full-year 2025 revenue of €477M and Q1 2026 revenue of €197M, with patient enrollments climbing from ~5,300 to over 6,300.

The M&A backdrop is real, but sizes matter

The deal environment underpinning this thesis has genuinely strengthened: 24 biopharma deals worth over $64B closed in the first four months of 2026 versus 14 deals worth $24.5B a year earlier, against a backdrop of $230B in revenue facing patent expiry by 2030. But deal structure has shifted toward $1B-$10B bolt-ons rather than mega-mergers, and antitrust regulators have kept the stricter 2023 merger guidelines in place rather than loosening them. That matters because ALNY ($39.9B), ASND ($16.7B) and CYTK ($11.5B) have all grown past the bolt-on sweet spot, even as speculative chatter persists -- Novartis and Amgen interest in Cytokinetics and unresolved takeover rumors around Ascendis. DYN ($2.86B), CGON ($5.9B), DNLI ($2.96B), MLTX ($1.29B) and PCVX ($8.4B) remain squarely in the range pharma is actually buying.

Catalysts still ahead

The binary readouts underpinning the bucket's re-rating haven't fired yet. Cytokinetics launched aficamten commercially in the EU in June 2026 following U.S. and China approvals. Vaxcyte's VAX-31 pivotal trial completed enrollment in March 2026, with topline data due Q4 2026. CG Oncology expects its cretostimogene BLA submission in Q4 2026 and holds cash into 2029, reducing near-term deal urgency for that name specifically. A biotech IPO and financing surge -- the strongest since the COVID era -- supports the broader re-rating thesis, but all eight names still carry deeply negative trailing earnings multiples, meaning the case rests on pipeline execution and takeout optionality rather than current fundamentals.